A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Hoffmann-La Roche485 enrolled

Overview

This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC. Participants will be enrolled at documentation of progression of disease (PD) after 4-6 cycles of first-line treatment with bevacizumab plus a platinum doublet-containing therapy and a minimum of two cycles of bevacizumab maintenance treatment prior to PD. Participants will be randomly assigned to one of two treatment arms to receive either bevacizumab plus SOC treatment or SOC treatment alone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

485

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed non-squamous NSCLC * Documented progression of disease (locally recurrent or metastatic) per investigator assessment following first-line treatment with 4-6 cycles of Bevacizumab plus a platinum doublet-containing chemotherapy regimen and a minimum of 2 cycles of Bevacizumab (monotherapy) maintenance treatment prior to first progression of disease * No treatment interruption of Bevacizumab treatment greater than 2 consecutive cycles (42 days) between the start of first-line treatment to start of Cycle 1 of second line treatment * Randomization within 4 weeks of progression of disease * At least one unidimensionally measurable lesion meeting RECIST v1.1 criteria * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Participants with adequate hematological, liver, and renal function * Female participants must not be pregnant or breast-feeding. Female participants of childbearing potential and fertile male participants must agree to use a highly effective contraceptive during the trial and for a period of at least 6 months following the last administration of trial drug(s) Exclusion Criteria: * Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component * Epidermal growth factor receptor (EGFR)-mutation-positive disease according to local laboratory testing * History of hemoptysis greater than or equal to (\>/=) grade 2 within 3 months of randomization * History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding and active gastrointestinal bleeding * Major cardiac disease * Treatment with any other investigational agent within 28 days prior to randomization * Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseen * Malignancy other than NSCLC within 5 years prior to randomization and evidence of any other disease that contraindicates the use of an investigational or SOC drug

Locations (179)

USA Mitchell Cancer Institute

Mobile, Alabama, United States

Palo Verde Hema/Onc

Glendale, Arizona, United States

Arizona Center for Cancer Care

Glendale, Arizona, United States

Clopton Clinic

Jonesboro, Arkansas, United States

East Valley Hematology ; Oncology Medical Group

Burbank, California, United States

Outcomes

Primary Outcomes

Overall Survival (OS)

Overall survival (OS) was defined as the time from the date of randomization at first progression of disease to the date of death, regardless of the cause of death.